Aignostics and Mayo Clinic Collaborate to Launch Revolutionary Pathology Model Advancing Medical Analytics
In an impressive stride toward enhancing medical diagnostics, Aignostics has announced the results of its latest research: a groundbreaking pathology foundation model developed in collaboration with Mayo Clinic Digital Pathology. This innovative model was created in just two months, utilizing a rich dataset of 1.2 million diverse slide images sourced from Mayo Clinic and Charité – Universitätsmedizin Berlin. This rapid development timeline sets a new precedent in the industry, showcasing both speed and efficiency alongside remarkable performance.
The new model establishes a new state-of-the-art benchmark, outperforming existing methodologies across more than twenty public benchmarks in pathology. Not only is its performance impressive, but it is also computationally efficient, making it a more practical option compared to many contemporary image-based models. The success of this model stems largely from Aignostics' pathologist-curated development methodology, which intricately weaves expert medical knowledge into the very fabric of its development process.
Maximilian Alber, the Chief Technology Officer of Aignostics, expressed immense excitement regarding this achievement, stating, "These results represent an exciting achievement in our collaboration with Mayo Clinic. Aignostics and Mayo Clinic have direct access to millions of additional training images and new data modalities, which will be integrated into the model over time, enhancing its capabilities and overall accuracy."
Such an advancement is not just academic; it has practical implications for healthcare and life sciences organizations worldwide. Organizations involved in research and clinical development will find this new model indispensable. Moreover, Aignostics plans to integrate this innovative model into its growing collection of AI-driven pathology products, enabling precise and generalizable solutions for biomarker, cell, and tissue image analysis. This duality – licensing of foundational technology alongside tailor-made applications – equips partner organizations with versatile tools to exploit the model's strengths as per their unique requirements.
Jim Rogers, CEO of Mayo Clinic Digital Pathology, emphasized the transformative potential of their collaboration, stating, "Mayo Clinic Digital Pathology will work with Aignostics to transform pathology for the benefit of patients everywhere." The sentiment was echoed by Viktor Matyas, CEO of Aignostics, who reflected, "These results show there is real potential in combining Mayo Clinic's vast medical expertise and resources with Aignostics' pioneering technologies. They underline our ambition and readiness to jointly lead in this space."
Aignostics, founded in 2018 as a spin-off from Charité Berlin, one of the premier university hospitals globally, is at the forefront of utilizing artificial intelligence to distill complex pathology data into actionable insights. Backed by notable investors, the company operates from Berlin and New York, focusing on precision medicine through collaboration with biopharma partners, which includes supporting drug discovery, translational research, clinical trials, and companion diagnostics development.
As a result of its innovative approach and commitment to excellence, Aignostics is poised to shape the future of medical analytics significantly. With the introduction of this new model, healthcare professionals are equipped with better tools for diagnosis, ultimately improving patient outcomes and advancing the field of pathology.
The new model establishes a new state-of-the-art benchmark, outperforming existing methodologies across more than twenty public benchmarks in pathology. Not only is its performance impressive, but it is also computationally efficient, making it a more practical option compared to many contemporary image-based models. The success of this model stems largely from Aignostics' pathologist-curated development methodology, which intricately weaves expert medical knowledge into the very fabric of its development process.
Maximilian Alber, the Chief Technology Officer of Aignostics, expressed immense excitement regarding this achievement, stating, "These results represent an exciting achievement in our collaboration with Mayo Clinic. Aignostics and Mayo Clinic have direct access to millions of additional training images and new data modalities, which will be integrated into the model over time, enhancing its capabilities and overall accuracy."
Such an advancement is not just academic; it has practical implications for healthcare and life sciences organizations worldwide. Organizations involved in research and clinical development will find this new model indispensable. Moreover, Aignostics plans to integrate this innovative model into its growing collection of AI-driven pathology products, enabling precise and generalizable solutions for biomarker, cell, and tissue image analysis. This duality – licensing of foundational technology alongside tailor-made applications – equips partner organizations with versatile tools to exploit the model's strengths as per their unique requirements.
Jim Rogers, CEO of Mayo Clinic Digital Pathology, emphasized the transformative potential of their collaboration, stating, "Mayo Clinic Digital Pathology will work with Aignostics to transform pathology for the benefit of patients everywhere." The sentiment was echoed by Viktor Matyas, CEO of Aignostics, who reflected, "These results show there is real potential in combining Mayo Clinic's vast medical expertise and resources with Aignostics' pioneering technologies. They underline our ambition and readiness to jointly lead in this space."
Aignostics, founded in 2018 as a spin-off from Charité Berlin, one of the premier university hospitals globally, is at the forefront of utilizing artificial intelligence to distill complex pathology data into actionable insights. Backed by notable investors, the company operates from Berlin and New York, focusing on precision medicine through collaboration with biopharma partners, which includes supporting drug discovery, translational research, clinical trials, and companion diagnostics development.
As a result of its innovative approach and commitment to excellence, Aignostics is poised to shape the future of medical analytics significantly. With the introduction of this new model, healthcare professionals are equipped with better tools for diagnosis, ultimately improving patient outcomes and advancing the field of pathology.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.